3 results
The primary objective is to evaluate the efficacy of avacopan compared to placebo based on histologic changes in kidney biopsies taken before and during treatment.The secondary objectives of this study include evaluation of:1. The safety of avacopan…
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide…
The BeyeOMARKER study*s primary aim is to (1) provide proof-of-concept for blood-based biomarkers as a tool for minimally invasive early detection of AD pathology in a diverse population from an alternative clinically relevant setting. Secondly, we…